The oncology landscape is approaching an unprecedented inflection point.
As several market-leading PD-(L)1 inhibitors face imminent loss of exclusivity (LoE), the industry confronts a stark reality: technological innovation alone no longer guarantees commercial success. Payers increasingly prioritize clinical outcomes over novel mechanisms of action, creating a complex web of access challenges that threaten to reshape how oncology products reach patients.
In Part 3 of this series on PD-(L)1 LoE, CRA’s Aaron Everitt looks at the current seismic shift—one that demands more than reactive strategies and requires a fundamental reimagining of how to approach pricing and market access in a post-patent cliff environment. Drawing on deep market access expertise, Everitt outlines a detailed framework of seven guiding principles designed to help pharma manufacturers navigate the challenging terrain, while also preserving the industry’s capacity for meaningful therapeutic advances.
While speculation abounds about how stakeholders will leverage these changes, the real question isn’t what will happen, but how forward-thinking organizations can build bridges to ensure that oncology remains a thriving ecosystem of innovation—one where patent cliffs become steppingstones, rather than stumbling blocks, to better patient outcomes.
